Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Sclerosis (MS) - Relapsing-remitting: full-pipeline trial registry
6 of 6 indexed Multiple Sclerosis (MS) - Relapsing-remitting trials are currently recruiting.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 6 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Multiple Sclerosis (MS) - Relapsing-remitting: 6 US clinical trials tracked, 6 recruiting.
Multiple Sclerosis (MS) - Relapsing-remitting is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Georgia State University, running 1 of these trials.
Enrollment posture brief
Registry condition multiple-sclerosis-ms-relapsing-remitting
OPEN 6 | RECR 100% | LATE 1 | EARLY 1 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Multiple Sclerosis (MS) - Relapsing-remitting lists 6 open slots (100% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Sclerosis (MS) - Relapsing-remitting on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Sclerosis (MS) - Relapsing-remitting is recruiting above its size-band peers.
6 of 6 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Multiple Sclerosis (MS) - Relapsing-remitting research.
Georgia State University accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Multiple Sclerosis (MS) - Relapsing-remitting trials plan to enrol fewer than 100 people.
Median target enrolment is 70 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.
-
Multiple Sclerosis (MS) - Relapsing-remitting research is mostly interventional.
5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
University of California, San Francisco
NCT07222618
Home Based Functional Balance Intervention for Multiple Sclerosis
University of Illinois at Chicago
NCT07355387
Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery
University of Colorado, Denver
NCT06641271
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Northwestern University
NCT07225361
Effects of Ublituximab on Motor Functions in Multiple Sclerosis
Georgia State University
NCT06629428
Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study
University of Florida
NCT07376772
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Sclerosis (MS) - Relapsing-remitting records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Sclerosis (MS) - Relapsing-remitting trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Sclerosis (MS) - Relapsing-remitting page
6 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Multiple Sclerosis (MS) - Relapsing-remitting trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Georgia State University sponsors the most Multiple Sclerosis (MS) - Relapsing-remitting trials on record, review their full trial history before evaluating a specific study. See Georgia State University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Sclerosis (MS) - Relapsing-remitting condition card totals 6 registered trials; most-linked intervention Ublituximab; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.